Pancreatic Cancer Research

ResearcherUniversity of Florida HealthActive in the last 2 years

Christopher E Forsmark

Matched on ORCID iD 0000-0002-2508-1543; OpenAlex author ID A5030058343, A5112798301; NIH RePORTER profile ID 1936982. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 1)
Trials
0
Grants
2
Labs led
1
Collaborators
73
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 3 papers · 2019: none · 2020: 5 papers · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 1 grant · 2025: 1 paper · 2026: 5 papers, 1 grant

Papers 20

  1. The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) 10 years of past accomplishments and looking forward to the next … Co-author DOI 10.1016/j.pan.2025.12.023↗
  2. Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancrea… Co-author DOI 10.1016/j.pan.2026.04.001↗
  3. Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. Co-author DOI 10.1016/j.pan.2026.04.020↗
  4. The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC): 10 Years of Past Accomplishments and Looking Forward to the Next… Co-author DOI 10.1097/mpa.0000000000002629↗
  5. Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report From the Consortium for the Study of Chronic Pancreatitis, Diabet… Co-author DOI 10.1097/mpa.0000000000002657↗
  6. Impact of Order Set on Exocrine Pancreatic Insufficiency in Chronic Pancreatitis, Pancreatic Cancer, and Pancreatic Resection. Last author DOI 10.1016/j.gastha.2024.08.019↗
  7. A peek at the other side of the coin: Tumor-suppressor role of microRNAs expressed by pancreatic cancer-associated fibroblasts. Co-author DOI 10.1002/ctm2.1357↗
  8. Impact of Biopsy Attempts, Race, and Access on Time to Initiation of Treatment for Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05531-6↗
  9. A protein-based machine learning approach to the identification of inflammatory subtypes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.06.007↗
  10. Consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer: achievements and future directions. First author DOI 10.1097/mog.0000000000000765↗
  11. Protein Signatures and Tissue Diagnosis of Pancreatic Cancer. Co-author DOI 10.1016/j.jamcollsurg.2019.10.002↗
  12. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  13. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsi… Co-author DOI 10.1111/apt.15698↗
  14. Letter: the under-treatment and under-diagnosis of pancreatic exocrine insufficiency in chronic pancreatitis and pancreatic cancer is just the tip of the icebe… Co-author DOI 10.1111/apt.15948↗
  15. Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/1756284820964319↗
  16. Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer: From Concept to Reality. Co-author DOI 10.1097/mpa.0000000000001167↗
  17. PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the … Co-author DOI 10.1097/mpa.0000000000001170↗
  18. Stroma-derived extracellular vesicles deliver tumor-suppressive miRNAs to pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.23532↗
  19. Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know. Co-author DOI 10.1016/j.pan.2015.11.009↗
  20. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Co-author DOI 10.1016/s2468-1253(16)30106-6↗

Grants 2

  1. The Chronic Pancreatitis Clinical Research Consortium U01DK144420↗
  2. U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS U01DK108320↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steven J. Hughes · 8 shared papers, 2 shared grants, 2018–2026 · strength 2.93
  2. Stephen Jacob Pandol · 9 shared papers, 2016–2026 · strength 2.46
  3. Dhiraj Yadav · 7 shared papers, 2016–2026 · strength 1.04
  4. Richard E Pratley · 1 shared grant, 2026 · strength 1.00
  5. Kenneth Cusi · 1 shared paper, 1 shared grant, 2024–2026 · strength 0.97
  6. Phil A. Hart · 5 shared papers, 2016–2026 · strength 0.83
  7. Evan L Fogel · 4 shared papers, 2018–2026 · strength 0.78
  8. Walter Gwang-Up Park · 4 shared papers, 2018–2026 · strength 0.78
  9. Dana K. Andersen · 4 shared papers, 2016–2026 · strength 0.61
  10. Kelly M. Herremans · 3 shared papers, 2023 · strength 0.58
  11. Song Han · 4 shared papers, 2018–2023 · strength 0.58
  12. Stephen K. Van Den Eeden · 3 shared papers, 2018–2026 · strength 0.53
  13. Melena D. Bellin · 3 shared papers, 2016–2026 · strength 0.52
  14. William E Fisher · 2 shared papers, 2026 · strength 0.49
  15. Santhi Swaroop Vege · 2 shared papers, 2026 · strength 0.47
  16. Suresh T. Chari · 4 shared papers, 2016–2026 · strength 0.44
  17. Jo Ann Rinaudo · 3 shared papers, 2018–2026 · strength 0.40
  18. Gerik W. Tushoski-Alemán · 2 shared papers, 2023 · strength 0.39
  19. José Serrano · 3 shared papers, 2018–2026 · strength 0.38
  20. Ibrahim Nassour · 2 shared papers, 2023 · strength 0.38
  21. Andrea N. Riner · 2 shared papers, 2023 · strength 0.38
  22. Randall E. Brand · 2 shared papers, 2020–2026 · strength 0.32
  23. Yogish C. Kudva · 2 shared papers, 2016–2026 · strength 0.30
  24. Mark Goodarzi · 2 shared papers, 2016–2026 · strength 0.30
  25. Patrick W. Underwood · 2 shared papers, 2020–2023 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.